Genetic Editing for ASCVD Market Revenue and Forecast by 2033

23 Jul 2025

Share :

Table of Content

1. Genetic Editing for ASCVD Market Revenue and Trends 2025 to 2033 2. What are the Key Factors Boosting the Growth of the Genetic Editing for ASCVD Market? 3. Segment Outlook 4. Regional Insights 5. Genetic Editing for ASCVD Market Coverage 6. Genetic Editing for ASCVD Market Key Players

Genetic Editing for ASCVD Market Revenue and Trends 2025 to 2033

The genetic editing for ASCVD market focuses on CRISPR, base editing, and other gene editing tools targeting lipid metabolism genes to prevent or treat cardiovascular disease. The growth of the market is driven by the rising incidence of ASCVD, ongoing advancements in research infrastructure, increasing demand for personalized cardiovascular therapies, and strong regulatory support.

What are the Key Factors Boosting the Growth of the Genetic Editing for ASCVD Market?

The market is undergoing rapid changes, driven by several key factors. Firstly, the rising incidence and prevalence of ASCVD globally, due to sedentary lifestyles and an aging population, is creating a strong demand for new therapies. Secondly, advancements in genetic editing technologies, such as CRISPR-Cas9, are enabling precise interventions and attracting increased research funding. Growing interest and investment, coupled with expanding regulations and public-private partnerships, are accelerating clinical trials and commercialization pathways. Thirdly, emerging data on the genetic causes of cardiovascular diseases are increasingly identifying at-risk individuals early on. This, in turn, is boosting the demand for early diagnoses and personalized medicine, further driving the growth of the genetic editing for ASCVD market.

Segment Outlook

• By editing modality, the CRISPR/Cas9 gene knockout segment dominated the market in 2024. The segment’s dominance stems from its accuracy, efficiency, and scalability, which make it the leading modality for targeted cardiovascular treatments.
• By therapeutic target, the PCSK9 segment held the largest share of the market in 2024. The segment’s dominance stems from its proven effectiveness in targeting cholesterol regulation and having also been highly effective with clinical success in gene-targeted therapies.
• By delivery system, the AAV vectors segment contributed the most revenue share in 2024. AAV vectors are the preferred delivery systems for administering gene therapies, as they offer high efficiency, safety, and enable long-term gene expression in cardiovascular tissues.
• By stage of development, the preclinical research segment holds a dominant position in the genetic editing for ASCVD market due to ongoing research into genetic markers associated with ASCVD. Rising investment in the development of novel tests further supports segmental growth.
• By end user, the pharmaceutical & biotechnology companies segment dominated the market with a major share in 2024. This is primarily due to their active participation in research and development, strategic partnerships and collaborations, as well as a continued commitment to expanding their clinical pipeline.

Regional Insights

North America maintained a stronghold in the genetic editing for ASCVD market. The region’s dominance is attributed to ongoing research and development in the field of genetic diseases. The region’s advanced healthcare infrastructure, favorable regulatory environment, and the presence of leading biotechnology companies further bolstered the market.

Meanwhile, Asia Pacific is emerging as the fastest-growing region due to increasing healthcare access and government spending on biotechnology R&D. The rising prevalence of ASCVD further supports market growth.

Genetic Editing for ASCVD Market Coverage

Recent development

• On July 12, 2025, Verve Therapeutics (now part of Eli Lilly) presented Phase 1 results for its base-editing therapy VERVE‑102, showing average LDL‑C reductions of ~53 %, and up to 69 % at higher doses, with good safety in initial cohorts.
  (Source: https://www.livescience.com)

Genetic Editing for ASCVD Market Key Players

• CRISPR Therapeutics
• Intellia Therapeutics
• Editas Medicine
• Beam Therapeutics
• Verve Therapeutics
• Sangamo Therapeutics
• Vertex Pharmaceuticals
• Novartis
• Allogene Therapeutics
• Crispr BioPharma
• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Precision BioSciences
• BlueRock Therapeutic
• Acuitas Therapeutics
• Moderna Therapeutics
• Pfizer
• Amgen
• BioNTech
• Evotec

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6440

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344